In a recent issue of Nature, Wang and colleagues revealed that CD300ld on PMN‐MDSCs is required for tumor‐driven immune suppression(1), this provided a new target for cancer immunotherapy, The study identified CD300ld as a novel, highly conserved tumor immunosuppressive receptor. This evidence concerns the gene CD300LD and neoplasm.